Impact of nanotechnology in breast cancer

Haq, Asif; Zabkiewicz, Catherine; Grange, Philippe; Arya, Manit

doi:10.1586/era.09.72

Cited by 8 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over the years, many investigators have been trying to develop paclitaxel nanoformulations that retain the anti-tumor properties of paclitaxel but reduce the non-specific toxicity related to the vehicles in which paclitaxel is delivered [32][33][34][35]. Many studies have shown that nanotechnology has a great potential not only to improve the characteristics of drugs that are hydrophobic and require the use of toxic solvents for delivery, but also increases the specificity of drugs by increasing the delivery of the drug to the targeted sites [20,[36][37][38][39].…”

Section: Discussionmentioning

confidence: 99%

In Vitro Efficacy Studies for Evaluating the Activity of a Self-assembled Nanoemulsion Formulation of Paclitaxel on Breast and Ovarian Cancer Cells

Bagul¹,

Kakumanu²,

Wilson

2014

Nano BioMed ENG

View full text Add to dashboard Cite

The drug of choice for treating breast and ovarian cancers is usually paclitaxel. This study was designed to evaluate the efficacy of a self-assembled nanoemulsion (SANE) of paclitaxel (NFP) on human breast (MCF-7) and ovarian (OVCAR-3) cancer cell lines. Cells were treated with various doses (1.2 nM-1200 nM of paclitaxel) as the NFP or suspended in DMSO (PSD). While both significantly inhibited cell proliferation of MCF-7 at doses >40 nM, at 12 nM the NFP significantly inhibited cell proliferation (-57%; p < 0.05) greater than the PSD (-5%). With OVCAR-3 cells, doses >12 nM for both significantly inhibited cell proliferation, but at 4 nM, the NFP significantly inhibited cell proliferation (-60%; p < 0.05) greater than the PSD (-23%). These results demonstrate that the effect of NFP on the cell proliferation of MCF-7 and OVCAR-3 cells are significantly greater at a lower dose than the PSD and that the NFP exhibited similar mode of action by induction of apoptosis and cell cycle arrest as the PSD. Therefore a SANE formulation of Paclitaxel has the potential to be a promising delivery system for anti-cancer drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

In Vitro Efficacy Studies for Evaluating the Activity of a Self-assembled Nanoemulsion Formulation of Paclitaxel on Breast and Ovarian Cancer Cells

Bagul¹,

Kakumanu²,

Wilson

2014

Nano BioMed ENG

View full text Add to dashboard Cite

show abstract

“… 3 Also, radio or chemotherapeutic agents are not targeted sufficiently; cause systemic effects and have poor penetration at the intended treatment site. 4 …”

Section: Introductionmentioning

confidence: 99%

“…3 Also, radio or chemotherapeutic agents are not targeted sufficiently; cause systemic effects and have poor penetration at the intended treatment site. 4 Pathogenic microbes are considered a serious problem as cancer may be stimulated by microbial infection and remain a serious problem in patients with advanced cancer. Thus, most patients treated with antineoplastic drugs are potential recipients of antimicrobial drugs.…”

Section: Introductionmentioning

confidence: 99%

Antitumor and Antibacterial Efficacy of Gallium Nanoparticles Coated by Ellagic Acid

et al. 2022

View full text Add to dashboard Cite

Cancer is a mortality contributor worldwide, and breast cancer is the most common among women. Despite the numerous breast cancer therapeutic strategies, they either have limitations or sometimes are resisted by cancer, so new approaches are needed to tackle those restrictions. Nanotechnology offers exciting leaps in the diagnosis and treatment of cancer, especially breast cancer. The main objective of this study was to investigate the effect of the newly synthesized gallium nanoparticles coated by Ellagic acid (EA-GaNPs) on the induced mammary gland carcinogenesis in female rats and their antibacterial activities comparison with standard antibiotics (Ketoconazole (100 μg/ml) and Gentamycin (4 μg/ml)) by disc diffusion method using eight different microbial species. The antitumor efficacy of EA-GaNPs was conducted both in vitro and in in vivo. The result of antimicrobial activity of EA-Ga NPs (1 mg/1 mL) revealed moderate toxicity behavior against Gram-positive {Staphylococcus aureus, Bacillus subtilis, Bacillus cereus) and Gram-negative pathogenic bacteria {Escherichia coli, Proteus vulgarfs) also, antifungal activity was detected against {Aspergillus terreus). In vitro study showed that EA-GaNPs inhibited human breast cancer cell line (MCF-7) proliferation with IC50 of 2.86 μg/ml. Although in vivo; the administration of EA-GaNPs to DMBA-treated rats ameliorated the hyperplastic state of mammary gland carcinogenesis induced by DMBA. Additionally, EA-GaNPs administration significantly modulated the activities of ALT and AST, as well as the levels of urea and creatinine in serum. Also, EA-GaNPs administration improved the antioxidant state by increasing Superoxide dismutase activity and GSH content, and decreasing malondialdehyde content in the mammary tissue, besides enhancing the apoptotic activity through elevating the levels of caspase-3 and decreasing the protein intensities of protein kinase B & phosphatidyl inositide 3-kinases. Furthermore, a significant decrease in serum Total iron-binding capacity accompanied by a significant increase in the level of calcium was noted. So, it can be concluded that the newly synthesized nanoparticles EA-GaNPs have an efficient antitumor activity that was manifested by reduction of the viability on the human breast cancer cell line (MCF-7) in vitro. Also, in vivo against the chemically induced mammary gland carcinogenesis in a female rat model. Histopathological findings were in harmony with biochemical and molecular results showing the effectiveness of EA-GaNPs against mammary carcinogenesis. Therefore, EA-GaNPs could be a promising, potent anti-cancer compound.

show abstract

“…Further, recent imaging possibilities are not sensitive at early stage, do not provide sufficient targeting capability, and can generate systemic effects. 3 Owing to above mentioned limitations, novel multifunctional technologies that present effective diagnosis, imaging, and successful therapy options are needed urgently for developing imaging and diagnostic based medicine for breast cancer. In this context, scientists and researchers have focused on the development of the nanoparticulate therapeutic systems, which contain multiple functionalities such as diagnostic and therapeutic actions into a single NP system.…”

Section: Introductionmentioning

confidence: 99%

Herceptin-conjugated magnetic polystyrene-Agsbox nanoparticles as a theranostic agent for breast cancer

2022

View full text Add to dashboard Cite

Breast cancer is a malignant tumor, which has derived from cells of the breast. Further, a relatively rapid metastasis, and resistance development against all the conventional drug combinations are major clinical issues in breast cancer patients as well as limitations like toxicity, genetic mutation, and metastasis make difficult the use of conventional therapy methods such as chemotherapy, radiotherapy, and local surgery. Therefore, considering the urgent needs, and high death rate in breast cancer cases, the development of new diagnosis and treatment regimens which diagnosed at the early stage and protected normal tissues required for clinical applications. Recently, the combination of tumor diagnosis and treatment within a single platform is a novel perspective, and magnetic nanoparticles are potential candidate owing to their low toxic effect, biocompatibility, biological degradability, superior magnetic properties, and targeting ability to overcome the problems of conventional diagnosis and therapy techniques. Considering these restrictions and requirements, the goal of this research was to investigate the potential of an innovative theranostic agent, which is soybean oil-based polystyrene (PS)-g-soybean oil graft copolymer containing AgNPs (PS-Agsbox) for treatment and MRI-based diagnosis of cancer. Herein, we designed targeted magnetic PS-Agsbox nanoparticles carrying thymoquinone (TQ) that is known for its anticancer potential against breast cancer, and herceptin (HER), which is to bind to the HER2 receptor protein on the surface of HER2-positive tumor cells, and acts by blocking the effects of it. We have successfully demonstrated selective binding, effective uptake of HER-conjugated magnetic PS-Agsbox nanoparticles into MDA-MB-231 (human breast carcinoma cells, a HER2-underexpressing cell line) and SKBR-3 (human breast cancer cells, a HER2-overexpressing breast cancer cell line) cell lines while no effect against L929 (mouse fibroblast cell line). Moreover, the magnetic resonance (MRI) properties of HER-conjugated magnetic PS-Agsbox nanoparticles were also confirmed.

show abstract

Impact of nanotechnology in breast cancer

Cited by 8 publications

References 21 publications

In Vitro Efficacy Studies for Evaluating the Activity of a Self-assembled Nanoemulsion Formulation of Paclitaxel on Breast and Ovarian Cancer Cells

In Vitro Efficacy Studies for Evaluating the Activity of a Self-assembled Nanoemulsion Formulation of Paclitaxel on Breast and Ovarian Cancer Cells

Antitumor and Antibacterial Efficacy of Gallium Nanoparticles Coated by Ellagic Acid

Herceptin-conjugated magnetic polystyrene-Agsbox nanoparticles as a theranostic agent for breast cancer

Contact Info

Product

Resources

About